These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38008068)

  • 1. Association between BMI and Efficacy of SGLT2 Inhibitors in Patients with Heart Failure or at Risk of Heart Failure: A Meta-Analysis Based on Randomized Controlled Trials.
    Zhou Y; Dai M; Huang T; Chen B; Xiang Z; Tang J; Zheng M; Guo L
    Cardiology; 2024; 149(2):104-116. PubMed ID: 38008068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials.
    Lee MC; Hua YM; Yang CT; Kuo FH; Chang WT; Tang HJ; Siong Toh H; Lin YM; Chen SY; Chang HY; Liao CT
    Medicine (Baltimore); 2022 Dec; 101(51):e32489. PubMed ID: 36595871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.
    Adamou A; Chlorogiannis DD; Kyriakoulis IG; Stamatiou I; Koukousaki D; Kardoutsos I; Sagris D; Doehner W; Ntaios G
    Intern Emerg Med; 2024 Mar; 19(2):565-573. PubMed ID: 38353880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
    JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis.
    Gager GM; Gelbenegger G; Jilma B; von Lewinski D; Sourij H; Eyileten C; Filipiak K; Postula M; Siller-Matula JM
    Front Cardiovasc Med; 2021; 8():691907. PubMed ID: 34336954
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
    ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
    Butler J; Usman MS; Khan MS; Greene SJ; Friede T; Vaduganathan M; Filippatos G; Coats AJS; Anker SD
    ESC Heart Fail; 2020 Dec; 7(6):3298-3309. PubMed ID: 33586910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
    Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C
    JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
    Cao Y; Li P; Li Y; Han Y
    ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
    Teo YH; Yoong CSY; Syn NL; Teo YN; Cheong JYA; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1453-1464. PubMed ID: 33942132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials.
    Jaiswal A; Jaiswal V; Ang SP; Hanif M; Vadhera A; Agrawal V; Kumar T; Nair AM; Borra V; Garimella V; Ishak A; Wajid Z; Song D; Attia AM; Huang H; Aguilera Alvarez VH; Shrestha AB; Biswas M
    Medicine (Baltimore); 2023 Sep; 102(39):e34693. PubMed ID: 37773799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
    Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
    Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.